Found 18 clinical trials
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.
- 0 views
- 19 Feb, 2024
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant …
- 0 views
- 19 Feb, 2024
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
- 0 views
- 18 May, 2025
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.
- 0 views
- 19 Feb, 2024
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
- 0 views
- 19 Feb, 2024
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- 0 views
- 19 Feb, 2024
A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX (cetuximab) in adults with recurrent and/or metastatic solid tumors.
- 0 views
- 19 Feb, 2024
Safety and Early Signs of Efficacy of IL12-L19L19.
The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas and diffuse large B-cell lymphoma (DLBCL), after previous immune checkpoint blockade therapy. The primary objective of the study is to …
- 0 views
- 19 Feb, 2024
- 1
- 2